Biomarker ID | 56 |
PMID | 15609297 |
Year | 2005 |
Biomarker | HEPSIN |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated (21 fold) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:- TGF-beta regulation of extracellular matrix, Interleukin-2 signaling pathway |
Experiment | Prostate Cancer Vs benign prostatic hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | 18 patients with prostate cancer and 35 patients with Benign Prostatic Hyperplasia (BPH) were tested against these 4 biomarkers to see how easily these 2 groups could be distinguished from one another |
Senstivity | BPH Predicion: 91.4% |
Specificity | PCa Prediction: 71.4% |
AUC | NA |
Accuracy | 83.9% |
Level Of Significance | p=0.049 |
Method Used | RT-PCR |
Clinical | No |
Remarks | The ratios of gene expression/10^5 copies of β2-microglobulin were calculated, in samples of PCa and BPH tissues |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | HPN |